Evidence map›Paper›PMID 31899221›Full record

ArticlePharmacology, biochemistry, and behavior2020

In vivo evaluation of the CB

Mohammed Mustafa, Giulia Donvito, Lauren Moncayo, Amelia Swafford, Justin Poklis, Ralph Grauer, Teresa Olszewska, Bogna Ignatowska-Jankowska, Debra A Kendall, Dai Lu and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Negative allosteric modulation of CBPharmacological research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Mohammed MustafaDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Giulia DonvitoDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Lauren MoncayoDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Amelia SwaffordDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Justin PoklisDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Ralph GrauerDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Teresa OlszewskaRangel College of Pharmacy, Health Science Center, Texas A&M University, Kingsville, TX, USA.
Bogna Ignatowska-JankowskaRangel College of Pharmacy, Health Science Center, Texas A&M University, Kingsville, TX, USA.
Debra A KendallDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, USA.
Dai LuRangel College of Pharmacy, Health Science Center, Texas A&M University, Kingsville, TX, USA.
Aron H LichtmanDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA; Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: aron.lichtman@vcuhealth.org.
Virginia Commonwealth University · USTexas A&M University – Kingsville · USUniversity of Connecticut · US

Funding

VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Matthew Sean Halquist · 2014 to 2026
$13.8M
CB1 Allosteric Modulators: Molecular, Cellular and In Vivo PharmacologyR01DA039942 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI KINSEY, STEVEN G., LICHTMAN, ARON H · 2016 to 2020
$2.6M
NIDA NIH HHS P30 DA033934NIDA NIH HHS R01 DA039942
6 · The paper itself

Abstract

In the present study, we examined whether LDK1258, which produces strong CB

Indexed as

Allosteric RegulationAmidohydrolasesAnalgesicsAnimalsAppetite DepressantsArachidonic AcidsBehavior, AnimalCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsChromatography, LiquidCyclohexanolsDisease Models, AnimalEndocannabinoidsFatty Acid Amide HydrolasesFemaleLocomotion3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolAmidohydrolasesAnalgesicsanandamideAppetite DepressantsArachidonic AcidsCannabinoid Receptor AgonistsCannabinoid Receptor AntagonistsCNR1 protein, mouseCyclohexanolsEndocannabinoidsFatty Acid Amide HydrolasesPolyunsaturated AlkamidesReceptor, Cannabinoid, CB1RimonabantAllosteric modulatorAnandamideCannabinoidCB(1) receptorCP55;940Drug discriminationNeuropathic painRimonabant

Identifiers

PMID31899221
PMCPMC8791624
OpenAlexW2997258507

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.